Form 4: Gilead Sciences Chief Medical Officer Merdad Parsey Reports Stock Sales

Chief Medical Officer of Gilead Sciences, Merdad Parsey, reports the sale of company stock under a pre-arranged trading plan.

Summary

• Merdad Parsey, the Chief Medical Officer of Gilead Sciences, reported the sale of 2,000 shares of common stock on February 28, 2024, at a price of $73.18 per share.
• He also sold 8,230 shares of common stock on February 29, 2024, at an average price of $72.7368 per share, with prices ranging from $72.454 to $72.88.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 9, 2023.
• Following these transactions, Parsey beneficially owns 92,706 shares of Gilead Sciences common stock, adjusted to reflect shares acquired under the Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions were pre-planned and don't necessarily indicate a negative outlook on the company's performance.

Industry Context

Insider trading activity is always closely watched by investors. While the sales were conducted under a pre-arranged trading plan, the market may still react to the news.

Stakeholder Impact

• Shareholders may react to the news of insider selling, even if it's under a pre-arranged plan.
• The impact on employees is likely minimal unless the selling is perceived as a lack of confidence in the company.

Key Dates